［1］张抒扬. 关爱罕见病,从保障用药开始\[J\]. 中国卫生, 2019, 405(5): 66-67.

［2］Zhao M, Wei DQ. Rare diseases: drug discovery and informatics resource\[J\]. Interdiscip Sci, 2018, 10(1): 195-204.

［3］Pulley JM, ShireyRice JK, Lavieri RR,  et al. Accelerating precision drug development and drug repurposing by leveraging human genetics\[J\]. Assay Drug Dev Technol, 2017, 15(3): 113-119.

［4］Ferreira CR. The burden of rare diseases\[J\]. Am J Med Genet A, 2019, 179(6):885-892.

［5］Mears AJ, Schock SC, Hadwen J, et al. Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cellbased drug screen\[J\]. NPJ Genom Med, 2017, 2: 14.

［6］Miller F, Zohar S, Stallard N, et al. Approaches to sample size calculation for clinical trials in rare diseases\[J\]. Pharm Stat, 2018, 17(3): 214-230.

［7］Park K. A review of computational drug repurposing\[J\]. Transl Clin Pharmacol, 2019, 27(2): 59-63.

［8］Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database\[J\]. Eur J Hum Genet, 2020, 28(2): 165-173.

［9］Zhu Q, Nguyen DT, Grishagin I, et al. An integrative knowledge graph for rare diseases, derived from the Genetic and Rare Diseases Information Center (GARD)\[J\]. J Biomed Semantics, 2020, 11(1): 13.

［10］李晓明, 马靖. FDA出台促进罕见病药物研发新策略\[J\]. 中国医药导刊, 2017, 9: 968-968.

［11］冯时, 刘爽, 弓孟春, 等.罕见病研究与孤儿药研发\[J\]. 国际药学研究杂志,2017, 44(2): 95-100.

［12］Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective\[J\]. Drug Discov Today Ther Strateg, 2011, 8(3-4): 61-69.

［13］Govindaraj RG, Naderi M, Singha M, et al. Largescale computational drug repositioning to find treatments for rare diseases\[J\]. NPJ Syst Biol Appl, 2018, 4: 13.

［14］Pantziarka P, Hutchinson L, André N,  et al. Next generation metronomic chemotherapyreport from the Fifth Biennial International Metronomic and Antiangiogenic Therapy Meeting, 68 May 2016, Mumbai\[J\]. Ecancermedicalscience, 2016, 10: 689.

［15］Hernandez JJ, Pryszlak M, Smith L, et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics\[J\]. Front Oncol, 2017,7: 273.

［16］LeBaron VT. Global cancer disparities and the need for new initiatives\[J\]. Oncol Nurs Forum, 2016, 43(1): 118-120.

［17］Pushpakom S, Iorio F, Eyers PA,  et al. Drug repurposing: progress, challenges and recommendations\[J\]. Nat Rev Drug Discov, 2019, 18(1): 41-58.

［18］Boyer A, Pasquier E, Tomasini P, et al. Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?\[J\]. Eur Respir Rev, 2018, 27(174): 170098.

［19］Grinnan D, Trankle C, Andruska A,  et al. Drug repositioning in pulmonary arterial hypertension: challenges and opportunities\[J\]. Pulm Circ, 2019, 9(1) 1-18.

［20］熊阿珍, 孟光兴. 药物重定位候选药物筛选路径\[J\]. 中国医药工业杂志, 2020, 51(2): 37-42.

［21］Lau EMT, Giannoulatou E, Celermajer DS,  et al. Epidemiology and treatment of pulmonary arterial hypertension\[J\]. Nat Rev Cardiol, 2017, 14(10): 603-614.

［22］Dodson MW, Brown LM, Elliott CG. Pulmonary arterial hypertension\[J\]. Heart Fail Clin, 2018,14(3): 255-269.

［23］赵瑶婉, 曹长春. 钙通道阻滞剂在儿童肾功能不全时的应用\[J\]. 江苏大学学报（医学版）, 1994, (4): 295-295.

［24］Sharma A, Obiagwu C, Mezue K, et al. Role of vasodilator testing in pulmonary hypertension\[J\]. Prog Cardiovasc Dis, 2016, 58(4): 425-433.

［25］Bhogal S, Khraisha O, Al Madani M, et al. Sildenafil for pulmonary arterial hypertension\[J\]. Am J Ther, 2019, 26(4): e520-e526.

［26］van der Graaf M, Rojer LA, Helbing W, et al. Express: Sildenafil for bronchopulmonary dysplasia and pulmonary hypertension: a metaanalysis\[J\]. Pulm Circ, 2019, 9(3): 1-8.

［27］LéautéLabrèze C, Harper JI, Hoeger PH. Infantile haemangioma\[J\]. Lancet, 2017, 390(10089): 85-94.

［28］Strandgren C, Revêchon G, SolaCarvajal A, et al. Emerging candidate treatment strategies for HutchinsonGilford progeria syndrome\[J\]. Biochem Soc Trans, 2017, 45(6): 1279-1293.

［29］Gordon LB, Kleinman ME, Massaro J,  et al. Clinical trial of the protein farnesylation inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in children with HutchinsonGilford progeria syndrome\[J\]. Circulation, 2016, 134(2): 114-125.

［30］Gordon LB, Shappell H, Massaro J,  et al. Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson Gilford Progeria syndrome\[J\]. JAMA, 2018, 319(16): 1687-1695.

［31］McGown A, Stopford MJ. Highthroughput drug screens for amyotrophic lateral sclerosis drug discovery\[J\]. Expert Opin Drug Discov, 2018, 13(11): 1015-1025.

［32］廖延婷, 王子安. 胃肠道间质瘤诊治的研究进展\[J\]. 中华全科医学,2018,16(2): 291-295.

［33］张文迪, 娄丽萍. 胃肠道间质瘤 KIT/PDGFRA 基因突变类型及其与临床病理特征的关系\[J\]. 江苏大学学报（医学版）, 2016, 26 (6): 492-498.

［34］Pessetto ZY, Weir SJ, Sethi G, et al. Drug  repurposing for gastrointestinal stromal tumor\[J\]. Mol Cancer Ther, 2013, 12(7): 1299-1309.

［35］Severino M, Bertamino M, Tortora D,  et al. Novel asymptomatic CNS findings in patients with ACVR1/ALK2 mutations causing fibrodysplasia ossificans progressive\[J\]. J Med Genet, 2016, 53(12): 859-864.

［36］Maruyama R, Yokota T. Morpholinomediated exon skipping targeting human ACVR1/ALK2 for fibrodysplasia ossificans progressiva\[J\]. Methods Mol Biol, 2018, 1828: 497-502.

［37］Yamamoto R, Matsushita M, Kitoh H,  et al. Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice\[J\]. J Bone Miner Metab, 2013, 31(1): 26-33.

［38］Brasil S, Pascoal C, Francisco R, et al. Artificial intelligence (AI) in rare diseases: is the future brighter? \[J\]. Genes (Basel), 2019, 10(12): 978.

［39］Brylinski M, Naderi M, Govindaraj RG, et al. eRepoORP: Exploring the opportunity space to combat orphan diseases with existing drugs\[J\]. J Mol Biol, 2018, 430(15): 2266-2273.

［40］Khaladkar M, Koscielny G, Hasan S, et al. Uncovering novel repositioning opportunities using the Open Targets platform\[J\]. Drug Discov Today, 2017, 22(12): 1800-1807.

［41］Lotfi Shahreza M, Ghadiri N, Green JR. A computational drug repositioning method applied to rare diseases: Adrenocortical carcinoma\[J\]. Sci Rep, 2020, 10(1): 8846.

［42］Landrum MJ, Lee JM, Riley GR,  et al. ClinVar: public archive of relationships among sequence variation and human phenotype\[J\]. Nucleic Acids Res, 2014, 42: D980-D985.

［43］Delavan B, Roberts R, Huang R,  et al. Computational drug repositioning for rare diseases in the era of precision medicine\[J\]. Drug Discov Today, 2018, 23(2): 382-394.

［44］Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis\[J\]. Lancet, 2017, 389 (10082): 1941-1952.

［45］Karatzas E, Bourdakou MM, Kolios G, et al. Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformaticsderived composite score\[J\]. Sci Rep, 2017, 7(1): 12569.

［46］Smpokou P, Zand DJ, Rosenbaum KN, et al. Malignancy in Noonan syndrome and related disorders\[J\]. Clin Genet, 2015, 88(6): 516-522.

［47］Kouz K, Lissewski C, Spranger S, et al. Genotype and phenotype in patients with Noonan syndrome and a RIT1 mutation\[J\]. Genet Med, 2016, 18(12):1226-1234.

［48］Zhu L, Roberts R, Huang R, et al. Drug repositioning for Noonan and LEOPARD syndromes by integrating transcriptomics with a structurebased approach\[J\]. Front Pharmacol, 2020, 11：927.

［49］Bibby AC, Tsim S, Kanellakis N, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment\[J\]. Eur Respir Rev, 2016, 25(142): 472-486.

［50］Oehl K, Vrugt B, Opitz I, et al. Heterogeneity in malignant pleural mesothelioma\[J\]. Int J Mol Sci, 2018, 19(6): 1603.

［51］Scherpereel A, Berghmans T, Lafitte JJ, et al. Valproatedoxorubicin: promising therapy for progressing mesothelioma. A phase Ⅱ study\[J\]. Eur Respir J, 2011, 37(1): 129-135.

［52］Baas P, Boogerd W, Dalesio O, et al. Thalidomide in patients with malignant pleural mesothelioma\[J\]. Lung Cancer, 2005, 48(2): 291-296.

［53］Buikhuisen WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after firstline chemotherapy (NVALT 5): an openlabel, multicentre, randomised phase 3 study\[J\]. Lancet Oncol, 2013, 14(6): 543-551.

［54］Jamil MO, Jerome MS, Miley D, et al. A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma\[J\]. Lung Cancer, 2017,8: 39-44.

［55］Bharadwaj PR, Bates KA, Porter T, et al. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases\[J\]. Transl Psychiatry, 2013, 3(12): e332.

［56］Cudkowicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multistage, randomised, doubleblind, placebocontrolled trial\[J\]. Lancet Neurol, 2014, 13(11):1083-1091.

［57］Banerjee I, De Leon D, Dunne MJ. Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient\[J\]. Orphanet J Rare Dis, 2017, 12(1): 70.

［58］Senniappan S, Alexandrescu S, Tatevian N,  et al. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia\[J\]. N Engl J Med, 2014, 370(12): 1131-1137.

［59］Senniappan S，Brown RE，Hussain K. Genomic and morphoproteomic correlates implicate the IGF1/mTOR/Akt pathway in the pathogenesis of diffuse congenital hyperinsulinism\[J\]. Int J Clin Exp Pathol, 2016, 9: 548-562.

［60］Szymanowski M, Estebanez MS, Padidela R, et al. Mammalian target of rapamycin (mTOR) inhibitors for the treatment of severe congenital hyperinsulinism in infancy: perspectives on limited therapeutic success\[J\]. J Clin Endocrinol Metab, 2016, 101(12): 4719-4729.